{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T19:06:38Z","timestamp":1794855998073,"version":"4.9.1"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T00:00:00Z","timestamp":1766620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07611-y","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T17:03:19Z","timestamp":1766682199000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antibody glycosylation in neuroimmune diseases"],"prefix":"10.1186","volume":"24","author":[{"given":"Kailin","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengchuan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhen","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijun","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanzhong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,25]]},"reference":[{"issue":"1","key":"7611_CR1","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41584-022-00867-4","volume":"19","author":"T Kissel","year":"2023","unstructured":"Kissel T, Toes REM, Huizinga TWJ, Wuhrer M. Glycobiology of rheumatic diseases. Nat Rev Rheumatol. 2023;19(1):28\u201343.","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"7611_CR2","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1093\/glycob\/cwac026","volume":"32","author":"N de Haan","year":"2022","unstructured":"de Haan N, Pu\u010di\u0107-Bakovi\u0107 M, Novokmet M, Falck D, Lageveen-Kammeijer G, Razdorov G, et al. Developments and perspectives in high-throughput protein glycomics: enabling the analysis of thousands of samples. Glycobiology. 2022;32(8):651\u201363.","journal-title":"Glycobiology"},{"issue":"2 Suppl 2","key":"7611_CR3","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.jaci.2009.09.046","volume":"125","author":"HW Schroeder Jr.","year":"2010","unstructured":"Schroeder HW Jr., Cavacini L. Structure and function of immunoglobulins. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S41\u201352.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"7611_CR4","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/glycob\/cwz048","volume":"30","author":"N de Haan","year":"2020","unstructured":"de Haan N, Falck D, Wuhrer M. Monitoring of immunoglobulin N- and O-glycosylation in health and disease. Glycobiology. 2020;30(4):226\u201340.","journal-title":"Glycobiology"},{"key":"7611_CR5","doi-asserted-by":"crossref","unstructured":"Li S, McCraw AJ, Gardner RA, Spencer DIR, Karagiannis SN, Wagner GK. Glycoengineering of therapeutic antibodies with small molecule inhibitors. Antibodies (Basel). 2021;10(4).","DOI":"10.3390\/antib10040044"},{"key":"7611_CR6","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","volume":"5","author":"G Vidarsson","year":"2014","unstructured":"Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520.","journal-title":"Front Immunol"},{"key":"7611_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1146\/annurev.immunol.25.022106.141702","volume":"25","author":"JN Arnold","year":"2007","unstructured":"Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The impact of glycosylation on the biological function and structure of human immunoglobulins. Annu Rev Immunol. 2007;25:21\u201350.","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"7611_CR8","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/nri3401","volume":"13","author":"I Schwab","year":"2013","unstructured":"Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol. 2013;13(3):176\u201389.","journal-title":"Nat Rev Immunol"},{"issue":"11\u201312","key":"7611_CR9","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1016\/j.molimm.2010.04.006","volume":"47","author":"GC Flynn","year":"2010","unstructured":"Flynn GC, Chen X, Liu YD, Shah B, Zhang Z. Naturally occurring glycan forms of human immunoglobulins G1 and G2. Mol Immunol. 2010;47(11\u201312):2074\u201382.","journal-title":"Mol Immunol"},{"issue":"11","key":"7611_CR10","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1074\/mcp.M114.039537","volume":"13","author":"A Bondt","year":"2014","unstructured":"Bondt A, Rombouts Y, Selman MH, Hensbergen PJ, Reiding KR, Hazes JM, et al. Immunoglobulin G (IgG) Fab glycosylation analysis using a new mass spectrometric high-throughput profiling method reveals pregnancy-associated changes. Mol Cell Proteomics. 2014;13(11):3029\u201339.","journal-title":"Mol Cell Proteomics"},{"issue":"10","key":"7611_CR11","doi-asserted-by":"publisher","first-page":"M111.010090","DOI":"10.1074\/mcp.M111.010090","volume":"10","author":"M Puci\u0107","year":"2011","unstructured":"Puci\u0107 M, Knezevi\u0107 A, Vidic J, Adamczyk B, Novokmet M, Polasek O, et al. High throughput isolation and glycosylation analysis of IgG-variability and heritability of the IgG glycome in three isolated human populations. Mol Cell Proteomics. 2011;10(10):M111.010090.","journal-title":"Mol Cell Proteomics"},{"issue":"2","key":"7611_CR12","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.jaci.2019.10.012","volume":"145","author":"HD Cheng","year":"2020","unstructured":"Cheng HD, Tirosh I, de Haan N, St\u00f6ckmann H, Adamczyk B, McManus CA, et al. IgG Fc glycosylation as an axis of humoral immunity in childhood. J Allergy Clin Immunol. 2020;145(2):710\u20133.e9.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"7611_CR13","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1021\/pr300887z","volume":"12","author":"MP Bakovi\u0107","year":"2013","unstructured":"Bakovi\u0107 MP, Selman MH, Hoffmann M, Rudan I, Campbell H, Deelder AM, et al. High-throughput IgG Fc N-glycosylation profiling by mass spectrometry of glycopeptides. J Proteome Res. 2013;12(2):821\u201331.","journal-title":"J Proteome Res"},{"key":"7611_CR14","doi-asserted-by":"publisher","first-page":"753294","DOI":"10.3389\/fimmu.2021.753294","volume":"12","author":"K Zlatina","year":"2021","unstructured":"Zlatina K, Galuska SP. Immunoglobulin glycosylation - an unexploited potential for immunomodulatory strategies in farm animals. Front Immunol. 2021;12:753294.","journal-title":"Front Immunol"},{"key":"7611_CR15","doi-asserted-by":"crossref","unstructured":"Kaminski HJ, Sikorski P, Coronel SI, Kusner LL. Myasthenia gravis: the future is here. J Clin Invest. 2024;134(12).","DOI":"10.1172\/JCI179742"},{"issue":"1","key":"7611_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41572-018-0027-2","volume":"4","author":"BC Kieseier","year":"2018","unstructured":"Kieseier BC, Mathey EK, Sommer C, Hartung HP. Immune-mediated neuropathies. Nat Rev Dis Primers. 2018;4(1):31.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"7611_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1055\/s-0044-1791579","volume":"45","author":"EM Monohan","year":"2025","unstructured":"Monohan EM, Brannagan TH 3rd. Immune-mediated neuropathies: top 10 clinical pearls. Semin Neurol. 2025;45(1):122\u201331.","journal-title":"Semin Neurol"},{"issue":"9","key":"7611_CR18","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6(9):805\u201315.","journal-title":"Lancet Neurol"},{"issue":"1","key":"7611_CR19","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","volume":"18","author":"E Carnero Contentti","year":"2021","unstructured":"Carnero Contentti E, Correale J. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies. J Neuroinflammation. 2021;18(1):208.","journal-title":"J Neuroinflammation"},{"issue":"20","key":"7611_CR20","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1001\/jama.2022.14236","volume":"328","author":"R Marcus","year":"2022","unstructured":"Marcus R. What is multiple sclerosis? Jama. 2022;328(20):2078.","journal-title":"Jama"},{"issue":"2","key":"7611_CR21","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378(2):169\u201380.","journal-title":"N Engl J Med"},{"issue":"9","key":"7611_CR22","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/S1474-4422(21)00218-0","volume":"20","author":"R Marignier","year":"2021","unstructured":"Marignier R, Hacohen Y, Cobo-Calvo A, Pr\u00f6bstel AK, Aktas O, Alexopoulos H, et al. Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol. 2021;20(9):762\u201372.","journal-title":"Lancet Neurol"},{"issue":"9","key":"7611_CR23","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1056\/NEJMra1708712","volume":"378","author":"J Dalmau","year":"2018","unstructured":"Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med. 2018;378(9):840\u201351.","journal-title":"N Engl J Med"},{"issue":"10","key":"7611_CR24","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14(10):1023\u201336.","journal-title":"Lancet Neurol"},{"issue":"2","key":"7611_CR25","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00401-023-02603-y","volume":"146","author":"MC Pham","year":"2023","unstructured":"Pham MC, Masi G, Patzina R, Obaid AH, Oxendine SR, Oh S, et al. Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology. Acta Neuropathol. 2023;146(2):319\u201336.","journal-title":"Acta Neuropathol"},{"issue":"8","key":"7611_CR26","first-page":"1637","volume":"18","author":"LN Zhu","year":"2023","unstructured":"Zhu LN, Hou HM, Wang S, Zhang S, Wang GG, Guo ZY, et al. FcRn inhibitors: a novel option for the treatment of myasthenia gravis. Neural Regen Res. 2023;18(8):1637\u201344.","journal-title":"Neural Regen Res"},{"issue":"4","key":"7611_CR27","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/mus.23944","volume":"49","author":"DB Sanders","year":"2014","unstructured":"Sanders DB, Burns TM, Cutter GR, Massey JM, Juel VC, Hobson-Webb L. Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis? Muscle Nerve. 2014;49(4):483\u201386.","journal-title":"Muscle Nerve"},{"key":"7611_CR28","doi-asserted-by":"publisher","first-page":"116671","DOI":"10.1016\/j.jns.2020.116671","volume":"410","author":"T Akaishi","year":"2020","unstructured":"Akaishi T, Takahashi T, Nakashima I, Abe M, Ishii T, Aoki M, et al. Repeated follow-up of AQP4-IgG titer by cell-based assay in neuromyelitis optica spectrum disorders (NMOSD). J Neurol Sci. 2020;410:116671.","journal-title":"J Neurol Sci"},{"issue":"5","key":"7611_CR29","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.cell.2010.04.012","volume":"141","author":"DF Zielinska","year":"2010","unstructured":"Zielinska DF, Gnad F, Wi\u015bniewski JR, Mann M. Precision mapping of an in vivo N-glycoproteome reveals rigid topological and sequence constraints. Cell. 2010;141(5):897\u2013907.","journal-title":"Cell"},{"issue":"11","key":"7611_CR30","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1016\/j.bbamcr.2013.04.001","volume":"1833","author":"M Aebi","year":"2013","unstructured":"Aebi M. N-linked protein glycosylation in the ER. Biochim Biophys Acta. 2013;1833(11):2430\u201337.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"7611_CR31","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.tibs.2009.10.001","volume":"35","author":"M Aebi","year":"2010","unstructured":"Aebi M, Bernasconi R, Clerc S, Molinari M. N-glycan structures: recognition and processing in the ER. Trends Biochem Sci. 2010;35(2):74\u201382.","journal-title":"Trends Biochem Sci"},{"issue":"1","key":"7611_CR32","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00018-009-0126-z","volume":"67","author":"L Tu","year":"2010","unstructured":"Tu L, Banfield DK. Localization of Golgi-resident glycosyltransferases. Cell Mol Life Sci. 2010;67(1):29\u201341.","journal-title":"Cell Mol Life Sci"},{"issue":"44","key":"7611_CR33","doi-asserted-by":"publisher","first-page":"38329","DOI":"10.1074\/jbc.M111.277681","volume":"286","author":"A Hassinen","year":"2011","unstructured":"Hassinen A, Pujol FM, Kokkonen N, Pieters C, Kihlstr\u00f6m M, Korhonen K, et al. Functional organization of Golgi N- and O-glycosylation pathways involves pH-dependent complex formation that is impaired in cancer cells. J Biol Chem. 2011;286(44):38329\u201340.","journal-title":"J Biol Chem"},{"issue":"3","key":"7611_CR34","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S0014-5793(00)01557-X","volume":"473","author":"K Masuda","year":"2000","unstructured":"Masuda K, Yamaguchi Y, Kato K, Takahashi N, Shimada I, Arata Y. Pairing of oligosaccharides in the Fc region of immunoglobulin G. FEBS Lett. 2000;473(3):349\u201357.","journal-title":"FEBS Lett"},{"issue":"22","key":"7611_CR35","doi-asserted-by":"publisher","first-page":"4070","DOI":"10.1002\/pmic.200700289","volume":"7","author":"M Wuhrer","year":"2007","unstructured":"Wuhrer M, Stam JC, van de Geijn FE, Koeleman CA, Verrips CT, Dolhain RJ, et al. Glycosylation profiling of immunoglobulin G (IgG) subclasses from human serum. Proteomics. 2007;7(22):4070\u201381.","journal-title":"Proteomics"},{"issue":"15","key":"7611_CR36","doi-asserted-by":"publisher","first-page":"15222","DOI":"10.18632\/aging.103884","volume":"12","author":"J \u0160tambuk","year":"2020","unstructured":"\u0160tambuk J, Naki\u0107 N, Vu\u010dkovi\u0107 F, Pu\u010di\u0107-Bakovi\u0107 M, Razdorov G, Trbojevi\u0107-Akma\u010di\u0107 I, et al. Global variability of the human IgG glycome. Aging (Albany NY). 2020;12(15):15222\u201359.","journal-title":"Aging (Albany NY)"},{"key":"7611_CR37","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cellimm.2018.07.009","volume":"333","author":"I Gudelj","year":"2018","unstructured":"Gudelj I, Lauc G, Pezer M. Immunoglobulin G glycosylation in aging and diseases. Cell Immunol. 2018;333:65\u201379.","journal-title":"Cell Immunol"},{"issue":"6","key":"7611_CR38","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1074\/mcp.M113.037465","volume":"13","author":"JE Huffman","year":"2014","unstructured":"Huffman JE, Pu\u010di\u0107-Bakovi\u0107 M, Klari\u0107 L, Hennig R, Selman MH, Vu\u010dkovi\u0107 F, et al. Comparative performance of four methods for high-throughput glycosylation analysis of immunoglobulin G in genetic and epidemiological research. Mol Cell Proteomics. 2014;13(6):1598\u2013610.","journal-title":"Mol Cell Proteomics"},{"issue":"2","key":"7611_CR39","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1021\/pr800737u","volume":"8","author":"A Knezevi\u0107","year":"2009","unstructured":"Knezevi\u0107 A, Polasek O, Gornik O, Rudan I, Campbell H, Hayward C, et al. Variability, heritability and environmental determinants of human plasma N-glycome. J Proteome Res. 2009;8(2):694\u2013701.","journal-title":"J Proteome Res"},{"issue":"4","key":"7611_CR40","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1074\/mcp.R112.026005","volume":"12","author":"G Zauner","year":"2013","unstructured":"Zauner G, Selman MH, Bondt A, Rombouts Y, Blank D, Deelder AM, et al. Glycoproteomic analysis of antibodies. Mol Cell Proteomics. 2013;12(4):856\u201365.","journal-title":"Mol Cell Proteomics"},{"issue":"8","key":"7611_CR41","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.4049\/jimmunol.1801622","volume":"202","author":"J Koers","year":"2019","unstructured":"Koers J, Derksen NIL, Ooijevaar-de Heer P, Nota B, van de Bovenkamp FS, Vidarsson G, et al. Biased N-Glycosylation site distribution and acquisition across the antibody V region during B cell maturation. J Immunol. 2019;202(8):2220\u201328.","journal-title":"J Immunol"},{"issue":"11","key":"7611_CR42","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.celrep.2015.11.027","volume":"13","author":"D Kao","year":"2015","unstructured":"Kao D, Danzer H, Collin M, Gro\u00df A, Eichler J, Stambuk J, et al. A monosaccharide residue is sufficient to maintain mouse and human IgG subclass activity and directs IgG effector functions to cellular Fc receptors. Cell Rep. 2015;13(11):2376\u201385.","journal-title":"Cell Rep"},{"issue":"4","key":"7611_CR43","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0161-5890(85)90125-7","volume":"22","author":"RJ Leatherbarrow","year":"1985","unstructured":"Leatherbarrow RJ, Rademacher TW, Dwek RA, Woof JM, Clark A, Burton DR, et al. Effector functions of a monoclonal aglycosylated mouse IgG2a: binding and activation of complement component C1 and interaction with human monocyte Fc receptor. Mol Immunol. 1985;22(4):407\u201315.","journal-title":"Mol Immunol"},{"issue":"1","key":"7611_CR44","first-page":"7","volume":"1","author":"D Zahavi","year":"2018","unstructured":"Zahavi D, AlDeghaither D, O\u2019Connell A, Weiner LM. Enhancing antibody-dependent cell-mediated cytotoxicity: a strategy for improving antibody-based immunotherapy. Antib Ther. 2018;1(1):7\u201312.","journal-title":"Antib Ther"},{"issue":"30","key":"7611_CR45","doi-asserted-by":"publisher","first-page":"26733","DOI":"10.1074\/jbc.M202069200","volume":"277","author":"RL Shields","year":"2002","unstructured":"Shields RL, Lai J, Keck R, O\u2019Connell LY, Hong K, Meng YG, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002;277(30):26733\u201340.","journal-title":"J Biol Chem"},{"issue":"8","key":"7611_CR46","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1080\/19420862.2016.1218586","volume":"8","author":"GP Subedi","year":"2016","unstructured":"Subedi GP, Barb AW. The immunoglobulin G1 N-glycan composition affects binding to each low affinity Fc \u03b3 receptor. MAbs. 2016;8(8):1512\u201324.","journal-title":"MAbs"},{"issue":"5","key":"7611_CR47","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.jmb.2004.01.007","volume":"336","author":"A Okazaki","year":"2004","unstructured":"Okazaki A, Shoji-Hosaka E, Nakamura K, Wakitani M, Uchida K, Kakita S, et al. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa. J Mol Biol. 2004;336(5):1239\u201349.","journal-title":"J Mol Biol"},{"issue":"1\u20132","key":"7611_CR48","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jim.2005.08.009","volume":"306","author":"R Niwa","year":"2005","unstructured":"Niwa R, Natsume A, Uehara A, Wakitani M, Iida S, Uchida K, et al. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides. J Immunol Methods. 2005;306(1\u20132):151\u201360.","journal-title":"J Immunol Methods"},{"issue":"1","key":"7611_CR49","doi-asserted-by":"publisher","first-page":"204","DOI":"10.4049\/jimmunol.1700116","volume":"199","author":"CW Bruggeman","year":"2017","unstructured":"Bruggeman CW, Dekkers G, Bentlage AEH, Treffers LW, Nagelkerke SQ, Lissenberg-Thunnissen S, et al. Enhanced effector functions due to antibody defucosylation depend on the effector cell Fc\u03b3 receptor profile. J Immunol. 2017;199(1):204\u201311.","journal-title":"J Immunol"},{"key":"7611_CR50","doi-asserted-by":"publisher","first-page":"641521","DOI":"10.3389\/fimmu.2021.641521","volume":"12","author":"A Karampatzakis","year":"2021","unstructured":"Karampatzakis A, Bro\u017e P, Rey C, \u00d6nfelt B, Cruz De Matos GDS, Rycroft D, et al. Antibody afucosylation augments CD16-mediated serial killing and IFN\u03b3 secretion by human natural killer cells. Front Immunol. 2021;12:641521.","journal-title":"Front Immunol"},{"issue":"12","key":"7611_CR51","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.4049\/jimmunol.1900985","volume":"203","author":"AR Temming","year":"2019","unstructured":"Temming AR, de Taeye SW, de Graaf EL, de Neef LA, Dekkers G, Bruggeman CW, et al. Functional attributes of antibodies, effector cells, and target cells affecting NK cell-mediated antibody-dependent cellular cytotoxicity. J Immunol. 2019;203(12):3126\u201335.","journal-title":"J Immunol"},{"issue":"25","key":"7611_CR52","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1182\/blood-2014-05-576835","volume":"124","author":"SQ Nagelkerke","year":"2014","unstructured":"Nagelkerke SQ, Dekkers G, Kustiawan I, van de Bovenkamp FS, Geissler J, Plomp R, et al. Inhibition of Fc\u03b3R-mediated phagocytosis by IVIg is independent of IgG-Fc sialylation and Fc\u03b3RIIb in human macrophages. Blood. 2014;124(25):3709\u201318.","journal-title":"Blood"},{"key":"7611_CR53","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3389\/fimmu.2017.00877","volume":"8","author":"G Dekkers","year":"2017","unstructured":"Dekkers G, Treffers L, Plomp R, Bentlage AEH, de Boer M, Koeleman CAM, et al. Decoding the human immunoglobulin G-Glycan repertoire reveals a spectrum of Fc-receptor- and complement-mediated-effector activities. Front Immunol. 2017;8:877.","journal-title":"Front Immunol"},{"issue":"5","key":"7611_CR54","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1080\/19420862.2018.1466767","volume":"10","author":"NA Pereira","year":"2018","unstructured":"Pereira NA, Chan KF, Lin PC, Song Z. The \u201cless-is-more\u201d in therapeutic antibodies: afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity. MAbs. 2018;10(5):693\u2013711.","journal-title":"MAbs"},{"issue":"5","key":"7611_CR55","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1074\/jbc.M210665200","volume":"278","author":"T Shinkawa","year":"2003","unstructured":"Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem. 2003;278(5):3466\u201373.","journal-title":"J Biol Chem"},{"issue":"46","key":"7611_CR56","doi-asserted-by":"publisher","first-page":"18975","DOI":"10.1021\/ja208390n","volume":"133","author":"G Zou","year":"2011","unstructured":"Zou G, Ochiai H, Huang W, Yang Q, Li C, Wang LX. Chemoenzymatic synthesis and Fc\u03b3 receptor binding of homogeneous glycoforms of antibody Fc domain. Presence of a bisecting sugar moiety enhances the affinity of Fc to Fc\u03b3IIIa receptor. J Am Chem Soc. 2011;133(46):18975\u201391.","journal-title":"J Am Chem Soc"},{"issue":"2","key":"7611_CR57","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/6179","volume":"17","author":"P Uma\u00f1a","year":"1999","unstructured":"Uma\u00f1a P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol. 1999;17(2):176\u201380.","journal-title":"Nat Biotechnol"},{"issue":"5","key":"7611_CR58","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1002\/bit.20777","volume":"93","author":"C Ferrara","year":"2006","unstructured":"Ferrara C, Br\u00fcnker P, Suter T, Moser S, P\u00fcntener U, Uma\u00f1a P. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II. Biotechnol Bioeng. 2006;93(5):851\u201361.","journal-title":"Biotechnol Bioeng"},{"issue":"1","key":"7611_CR59","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/s41467-020-14794-z","volume":"11","author":"A Garc\u00eda-Garc\u00eda","year":"2020","unstructured":"Garc\u00eda-Garc\u00eda A, Ceballos-Laita L, Serna S, Artschwager R, Reichardt NC, Corzana F, et al. Structural basis for substrate specificity and catalysis of \u03b11, 6-fucosyltransferase. Nat Commun. 2020;11(1):973.","journal-title":"Nat Commun"},{"issue":"17","key":"7611_CR60","doi-asserted-by":"publisher","first-page":"7934","DOI":"10.1158\/0008-5472.CAN-04-4212","volume":"65","author":"M Schuster","year":"2005","unstructured":"Schuster M, Umana P, Ferrara C, Br\u00fcnker P, Gerdes C, Waxenecker G, et al. Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering. Cancer Res. 2005;65(17):7934\u201341.","journal-title":"Cancer Res"},{"issue":"6","key":"7611_CR61","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1021\/bp050228w","volume":"21","author":"J Hodoniczky","year":"2005","unstructured":"Hodoniczky J, Zheng YZ, James DC. Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro. Biotechnol Prog. 2005;21(6):1644\u201352.","journal-title":"Biotechnol Prog"},{"issue":"8","key":"7611_CR62","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/glycob\/5.8.813","volume":"5","author":"MR Lifely","year":"1995","unstructured":"Lifely MR, Hale C, Boyce S, Keen MJ, Phillips J. Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions. Glycobiology. 1995;5(8):813\u201322.","journal-title":"Glycobiology"},{"issue":"2","key":"7611_CR63","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1080\/19420862.2018.1551044","volume":"11","author":"R Wada","year":"2019","unstructured":"Wada R, Matsui M, Kawasaki N. Influence of N-glycosylation on effector functions and thermal stability of glycoengineered IgG1 monoclonal antibody with homogeneous glycoforms. MAbs. 2019;11(2):350\u201372.","journal-title":"MAbs"},{"key":"7611_CR64","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3389\/fimmu.2017.00646","volume":"8","author":"B Peschke","year":"2017","unstructured":"Peschke B, Keller CW, Weber P, Quast I, L\u00fcnemann JD. Fc-galactosylation of human immunoglobulin gamma isotypes improves C1q binding and enhances complement-dependent cytotoxicity. Front Immunol. 2017;8:646.","journal-title":"Front Immunol"},{"key":"7611_CR65","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3389\/fimmu.2018.00553","volume":"9","author":"G Dekkers","year":"2018","unstructured":"Dekkers G, Rispens T, Vidarsson G. Novel concepts of altered immunoglobulin G galactosylation in autoimmune diseases. Front Immunol. 2018;9:553.","journal-title":"Front Immunol"},{"issue":"11","key":"7611_CR66","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.4049\/jimmunol.2300307","volume":"211","author":"T Damelang","year":"2023","unstructured":"Damelang T, de Taeye SW, Rentenaar R, Roya-Kouchaki K, de Boer E, Derksen NIL, et al. The influence of human IgG subclass and allotype on complement activation. J Immunol. 2023;211(11):1725\u201335.","journal-title":"J Immunol"},{"issue":"11","key":"7611_CR67","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1172\/JCI82695","volume":"125","author":"I Quast","year":"2015","unstructured":"Quast I, Keller CW, Maurer MA, Giddens JP, Tackenberg B, Wang LX, et al. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity. J Clin Invest. 2015;125(11):4160\u201370.","journal-title":"J Clin Invest"},{"issue":"12","key":"7611_CR68","doi-asserted-by":"publisher","first-page":"e0143520","DOI":"10.1371\/journal.pone.0143520","volume":"10","author":"T Dashivets","year":"2015","unstructured":"Dashivets T, Thomann M, Rueger P, Knaupp A, Buchner J, Schlothauer T. Multi-angle effector function analysis of human monoclonal IgG glycovariants. PLoS One. 2015;10(12):e0143520.","journal-title":"PLoS One"},{"issue":"8","key":"7611_CR69","doi-asserted-by":"publisher","first-page":"e0134949","DOI":"10.1371\/journal.pone.0134949","volume":"10","author":"M Thomann","year":"2015","unstructured":"Thomann M, Schlothauer T, Dashivets T, Malik S, Avenal C, Bulau P, et al. In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity. PLoS One. 2015;10(8):e0134949.","journal-title":"PLoS One"},{"key":"7611_CR70","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.molimm.2016.03.002","volume":"73","author":"M Thomann","year":"2016","unstructured":"Thomann M, Reckermann K, Reusch D, Prasser J, Tejada ML. Fc-galactosylation modulates antibody-dependent cellular cytotoxicity of therapeutic antibodies. Mol Immunol. 2016;73:69\u201375.","journal-title":"Mol Immunol"},{"issue":"9","key":"7611_CR71","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/nm.2862","volume":"18","author":"CM Karsten","year":"2012","unstructured":"Karsten CM, Pandey MK, Figge J, Kilchenstein R, Taylor PR, Rosas M, et al. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of Fc\u03b3RIIB and dectin-1. Nat Med. 2012;18(9):1401\u201306.","journal-title":"Nat Med"},{"issue":"1","key":"7611_CR72","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.bbrc.2016.09.038","volume":"479","author":"KA Heyl","year":"2016","unstructured":"Heyl KA, Karsten CM, Slevogt H. Galectin-3 binds highly galactosylated IgG1 and is crucial for the IgG1 complex mediated inhibition of C5aReceptor induced immune responses. Biochem Biophys Res Commun. 2016;479(1):86\u201390.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6 Pt A","key":"7611_CR73","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/j.bbadis.2018.03.018","volume":"1864","author":"I Gudelj","year":"2018","unstructured":"Gudelj I, Salo PP, Trbojevi\u0107-Akma\u010di\u0107 I, Albers M, Primorac D, Perola M, et al. Low galactosylation of IgG associates with higher risk for future diagnosis of rheumatoid arthritis during 10 years of follow-up. Biochim Biophys Acta Mol Basis Dis. 2018;1864(6 Pt A):2034\u201339.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"1","key":"7611_CR74","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1136\/annrheumdis-2013-203565","volume":"74","author":"Y Rombouts","year":"2015","unstructured":"Rombouts Y, Ewing E, van de Stadt LA, Selman MH, Trouw LA, Deelder AM, et al. Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. Ann Rheum Dis. 2015;74(1):234\u201341.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"7611_CR75","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1053\/j.gastro.2018.01.002","volume":"154","author":"M \u0160imurina","year":"2018","unstructured":"\u0160imurina M, de Haan N, Vu\u010dkovi\u0107 F, Kennedy NA, \u0160tambuk J, Falck D, et al. Glycosylation of immunoglobulin G associates with clinical features of inflammatory bowel diseases. Gastroenterology. 2018;154(5):1320\u201333.e10.","journal-title":"Gastroenterology"},{"key":"7611_CR76","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ebiom.2017.01.033","volume":"17","author":"MJ Kemna","year":"2017","unstructured":"Kemna MJ, Plomp R, van Paassen P, Koeleman CAM, Jansen BC, Damoiseaux J, et al. Galactosylation and sialylation levels of IgG predict relapse in patients with PR3-ANCA associated vasculitis. EBioMedicine. 2017;17:108\u201318.","journal-title":"EBioMedicine"},{"issue":"6176","key":"7611_CR77","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.1248943","volume":"343","author":"CA Diebolder","year":"2014","unstructured":"Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, et al. Complement is activated by IgG hexamers assembled at the cell surface. Science. 2014;343(6176):1260\u201363.","journal-title":"Science"},{"issue":"6","key":"7611_CR78","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.4049\/jimmunol.2100399","volume":"207","author":"TLJ van Osch","year":"2021","unstructured":"van Osch TLJ, Nouta J, Derksen NIL, van Mierlo G, van der Schoot CE, Wuhrer M, et al. Fc galactosylation promotes hexamerization of human IgG1, leading to enhanced classical complement activation. J Immunol. 2021;207(6):1545\u201354.","journal-title":"J Immunol"},{"issue":"7","key":"7611_CR79","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/art.42098","volume":"74","author":"T Kissel","year":"2022","unstructured":"Kissel T, Hafkenscheid L, Wesemael TJ, Tamai M, Kawashiri SY, Kawakami A, et al. IgG anti-citrullinated protein antibody variable domain glycosylation increases before the onset of rheumatoid arthritis and stabilizes thereafter: a cross-sectional study encompassing ~1,500 samples. Arthritis Rheumatol. 2022;74(7):1147\u201358.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"7611_CR80","doi-asserted-by":"publisher","first-page":"4522","DOI":"10.1021\/pr400589m","volume":"12","author":"A Bondt","year":"2013","unstructured":"Bondt A, Selman MH, Deelder AM, Hazes JM, Willemsen SP, Wuhrer M, et al. Association between galactosylation of immunoglobulin G and improvement of rheumatoid arthritis during pregnancy is independent of sialylation. J Proteome Res. 2013;12(10):4522\u201331.","journal-title":"J Proteome Res"},{"key":"7611_CR81","doi-asserted-by":"crossref","unstructured":"Szab\u00f3 D, Gyebrovszki B, Szarka E, Auer F, Rojkovich B, Nagy G, et al. Immunoglobulin G subclass-specific glycosylation changes in rheumatoid arthritis. Int J Mol Sci. 2025;26(19).","DOI":"10.3390\/ijms26199626"},{"issue":"1","key":"7611_CR82","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1006\/jaut.1996.0104","volume":"10","author":"A Bond","year":"1997","unstructured":"Bond A, Alavi A, Axford JS, Bourke BE, Bruckner FE, Kerr MA, et al. A detailed lectin analysis of IgG glycosylation, demonstrating disease specific changes in terminal galactose and N-acetylglucosamine. J Autoimmun. 1997;10(1):77\u201385.","journal-title":"J Autoimmun"},{"issue":"6","key":"7611_CR83","first-page":"1237","volume":"21","author":"I Trbojevi\u0107 Akma\u010di\u0107","year":"2015","unstructured":"Trbojevi\u0107 Akma\u010di\u0107 I, Ventham NT, Theodoratou E, Vu\u010dkovi\u0107 F, Kennedy NA, Kri\u0161ti\u0107 J, et al. Inflammatory bowel disease associates with proinflammatory potential of the immunoglobulin G glycome. Inflamm Bowel Dis. 2015;21(6):1237\u201347.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"7611_CR84","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/ibd.21459","volume":"17","author":"S Nakajima","year":"2011","unstructured":"Nakajima S, Iijima H, Shinzaki S, Egawa S, Inoue T, Mukai A, et al. Functional analysis of agalactosyl IgG in inflammatory bowel disease patients. Inflamm Bowel Dis. 2011;17(4):927\u201336.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"7611_CR85","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1093\/rheumatology\/keab416","volume":"61","author":"T Liu","year":"2022","unstructured":"Liu T, Han J, Zhang R, Tang Z, Yi G, Gong W, et al. Characteristics of purified anti-\u03b22GPI IgG N-glycosylation associate with thrombotic, obstetric and catastrophic antiphospholipid syndrome. Rheumatology (Oxford). 2022;61(3):1243\u201354.","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"7611_CR86","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1021\/acs.jproteome.6b00768","volume":"16","author":"S Mittermayr","year":"2017","unstructured":"Mittermayr S, L\u00ea GN, Clarke C, Mill\u00e1n Mart\u00edn S, Larkin AM, O\u2019Gorman P, et al. Polyclonal immunoglobulin G N-Glycosylation in the pathogenesis of plasma cell disorders. J Proteome Res. 2017;16(2):748\u201362.","journal-title":"J Proteome Res"},{"issue":"5","key":"7611_CR87","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1159\/000079484","volume":"66","author":"Y Kanoh","year":"2004","unstructured":"Kanoh Y, Mashiko T, Danbara M, Takayama Y, Ohtani S, Imasaki T, et al. Analysis of the oligosaccharide chain of human serum immunoglobulin G in patients with localized or metastatic cancer. Oncology. 2004;66(5):365\u201370.","journal-title":"Oncology"},{"issue":"10","key":"7611_CR88","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1016\/j.jprot.2012.02.001","volume":"75","author":"G Chen","year":"2012","unstructured":"Chen G, Wang Y, Qiu L, Qin X, Liu H, Wang X, et al. Human IgG Fc-glycosylation profiling reveals associations with age, sex, female sex hormones and thyroid cancer. J Proteomics. 2012;75(10):2824\u201334.","journal-title":"J Proteomics"},{"issue":"7","key":"7611_CR89","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1093\/glycob\/cwr027","volume":"21","author":"AM Goetze","year":"2011","unstructured":"Goetze AM, Liu YD, Zhang Z, Shah B, Lee E, Bondarenko PV, et al. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology. 2011;21(7):949\u201359.","journal-title":"Glycobiology"},{"key":"7611_CR90","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.3389\/fimmu.2018.02485","volume":"9","author":"MJ Buettner","year":"2018","unstructured":"Buettner MJ, Shah SR, Saeui CT, Ariss R, Yarema KJ. Improving immunotherapy through glycodesign. Front Immunol. 2018;9:2485.","journal-title":"Front Immunol"},{"issue":"1","key":"7611_CR91","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/glycob\/cwl057","volume":"17","author":"Y Kanda","year":"2007","unstructured":"Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology. 2007;17(1):104\u201318.","journal-title":"Glycobiology"},{"issue":"6027","key":"7611_CR92","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/316452a0","volume":"316","author":"RB Parekh","year":"1985","unstructured":"Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A, Stanworth D, et al. Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature. 1985;316(6027):452\u201357.","journal-title":"Nature"},{"issue":"12","key":"7611_CR93","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41577-021-00543-w","volume":"21","author":"H Pruss","year":"2021","unstructured":"Pruss H. Autoantibodies in neurological disease. Nat Rev Immunol. 2021;21(12):798\u2013813.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"7611_CR94","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41467-023-44468-5","volume":"15","author":"T Kissel","year":"2024","unstructured":"Kissel T, Derksen V, Bentlage AEH, Koeleman C, Hafkenscheid L, van der Woude D, et al. N-linked Fc glycosylation is not required for IgG-B-cell receptor function in a GC-derived B-cell line. Nat Commun. 2024;15(1):393.","journal-title":"Nat Commun"},{"issue":"2","key":"7611_CR95","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s10719-012-9381-6","volume":"30","author":"HK Einarsdottir","year":"2013","unstructured":"Einarsdottir HK, Selman MH, Kapur R, Scherjon S, Koeleman CA, Deelder AM, et al. Comparison of the Fc glycosylation of fetal and maternal immunoglobulin G. Glycoconj J. 2013;30(2):147\u201357.","journal-title":"Glycoconj J"},{"issue":"23","key":"7611_CR96","doi-asserted-by":"publisher","first-page":"12943","DOI":"10.1073\/pnas.2004325117","volume":"117","author":"S Borghi","year":"2020","unstructured":"Borghi S, Bournazos S, Thulin NK, Li C, Gajewski A, Sherwood RW, et al. FcRn, but not Fc\u03b3Rs, drives maternal-fetal transplacental transport of human IgG antibodies. Proc Natl Acad Sci U S A. 2020;117(23):12943\u201351.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"7611_CR97","doi-asserted-by":"publisher","first-page":"6994","DOI":"10.1016\/j.cell.2024.09.038","volume":"187","author":"DE Sastre","year":"2024","unstructured":"Sastre DE, Bournazos S, Du J, Boder EJ, Edgar JE, Azzam T, et al. Potent efficacy of an IgG-specific endoglycosidase against IgG-mediated pathologies. Cell. 2024;187(24):6994\u20137007.e12.","journal-title":"Cell"},{"issue":"9","key":"7611_CR98","doi-asserted-by":"publisher","first-page":"6591","DOI":"10.1074\/jbc.M009483200","volume":"276","author":"RL Shields","year":"2001","unstructured":"Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2001;276(9):6591\u2013604.","journal-title":"J Biol Chem"},{"issue":"9","key":"7611_CR99","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.str.2015.06.015","volume":"23","author":"GP Subedi","year":"2015","unstructured":"Subedi GP, Barb AW. The structural role of antibody N-Glycosylation in receptor interactions. Structure. 2015;23(9):1573\u201383.","journal-title":"Structure"},{"issue":"4","key":"7611_CR100","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.neuron.2018.01.021","volume":"97","author":"C Baecher-Allan","year":"2018","unstructured":"Baecher-Allan C, Kaskow BJ, Weiner HL. Multiple sclerosis: mechanisms and immunotherapy. Neuron. 2018;97(4):742\u201368.","journal-title":"Neuron"},{"key":"7611_CR101","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12974-015-0450-1","volume":"12","author":"M Wuhrer","year":"2015","unstructured":"Wuhrer M, Selman MH, McDonnell LA, K\u00fcmpfel T, Derfuss T, Khademi M, et al. Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid. J Neuroinflammation. 2015;12:235.","journal-title":"J Neuroinflammation"},{"issue":"14","key":"7611_CR102","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1177\/1352458516631036","volume":"22","author":"Y Decker","year":"2016","unstructured":"Decker Y, Schomburg R, N\u00e9meth E, Vitkin A, Fousse M, Liu Y, et al. Abnormal galactosylation of immunoglobulin G in cerebrospinal fluid of multiple sclerosis patients. Mult Scler. 2016;22(14):1794\u2013803.","journal-title":"Mult Scler"},{"issue":"1\u20132","key":"7611_CR103","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1007\/s11481-021-09996-1","volume":"17","author":"PGE Kennedy","year":"2022","unstructured":"Kennedy PGE, Graner M, Pointon T, Li X, Tanimoto K, Dennison K, et al. Aberrant immunoglobulin G glycosylation in multiple sclerosis. J Neuroimmune Pharmacol. 2022;17(1\u20132):218\u201327.","journal-title":"J Neuroimmune Pharmacol"},{"key":"7611_CR104","doi-asserted-by":"crossref","unstructured":"Cvetko A, Kifer D, Gornik O, Klari\u0107 L, Visser E, Lauc G, et al. Glycosylation alterations in multiple sclerosis show increased proinflammatory potential. Biomedicines. 2020;8(10).","DOI":"10.3390\/biomedicines8100410"},{"issue":"4","key":"7611_CR105","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1039\/D4AY01639D","volume":"17","author":"F \u015eahin","year":"2025","unstructured":"\u015eahin F, Kaya ZZ, Serteser M, \u00d6zt\u00fcrk H, Baykal AT. Glycan profiling of multiple sclerosis oligoclonal bands with MALDI-TOF. Anal Methods. 2025;17(4):850\u201358.","journal-title":"Anal Methods"},{"issue":"1","key":"7611_CR106","doi-asserted-by":"publisher","first-page":"14770","DOI":"10.1038\/s41598-025-99226-y","volume":"15","author":"AM Valk","year":"2025","unstructured":"Valk AM, Koers J, Derksen NIL, Hogenboom L, van Kempen Z, Killestein J, et al. Elevated Fab glycosylation of autoantibodies maintained during B cell depletion therapy. Sci Rep. 2025;15(1):14770.","journal-title":"Sci Rep"},{"key":"7611_CR107","doi-asserted-by":"publisher","first-page":"1357475","DOI":"10.3389\/fimmu.2024.1357475","volume":"15","author":"S Gao","year":"2024","unstructured":"Gao S, Jiao X, Guo R, Song X, Li B, Guo L. Reduced serum IgG galactosylation is associated with increased inflammation during relapses of neuromyelitis optica spectrum disorders. Front Immunol. 2024;15:1357475.","journal-title":"Front Immunol"},{"issue":"1","key":"7611_CR108","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/ana.23741","volume":"73","author":"L Tradtrantip","year":"2013","unstructured":"Tradtrantip L, Ratelade J, Zhang H, Verkman AS. Enzymatic deglycosylation converts pathogenic neuromyelitis optica anti-aquaporin-4 immunoglobulin G into therapeutic antibody. Ann Neurol. 2013;73(1):77\u201385.","journal-title":"Ann Neurol"},{"issue":"3","key":"7611_CR109","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1021\/pr401213z","volume":"13","author":"WJ Fokkink","year":"2014","unstructured":"Fokkink WJ, Selman MH, Dortland JR, Durmu\u015f B, Kuitwaard K, Huizinga R, et al. IgG Fc N-glycosylation in Guillain-Barr\u00e9 syndrome treated with immunoglobulins. J Proteome Res. 2014;13(3):1722\u201330.","journal-title":"J Proteome Res"},{"issue":"1","key":"7611_CR110","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1021\/pr1004373","volume":"10","author":"MH Selman","year":"2011","unstructured":"Selman MH, Niks EH, Titulaer MJ, Verschuuren JJ, Wuhrer M, Deelder AM. IgG fc N-glycosylation changes in Lambert-Eaton myasthenic syndrome and myasthenia gravis. J Proteome Res. 2011;10(1):143\u201352.","journal-title":"J Proteome Res"},{"issue":"8","key":"7611_CR111","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.4049\/jimmunol.2100225","volume":"207","author":"C Mandel-Brehm","year":"2021","unstructured":"Mandel-Brehm C, Fichtner ML, Jiang R, Winton VJ, Vazquez SE, Pham MC, et al. Elevated N-Linked glycosylation of IgG V regions in myasthenia gravis disease subtypes. J Immunol. 2021;207(8):2005\u201314.","journal-title":"J Immunol"},{"issue":"6","key":"7611_CR112","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/j.jaci.2022.10.035","volume":"151","author":"J Koers","year":"2023","unstructured":"Koers J, Sciarrillo R, Derksen NIL, Vletter EM, Fillie-Grijpma YE, Raveling-Eelsing E, et al. Differences in IgG autoantibody Fab glycosylation across autoimmune diseases. J Allergy Clin Immunol. 2023;151(6):1646\u201354.","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"7611_CR113","doi-asserted-by":"publisher","first-page":"965","DOI":"10.29271\/jcpsp.2021.08.965","volume":"31","author":"U Ullah","year":"2021","unstructured":"Ullah U, Iftikhar S, Javed MA. Relationship between low and high anti-acetylcholine receptor antibody titers and clinical severity in myasthenia gravis. J Coll Physicians Surg Pak. 2021;31(8):965\u201368.","journal-title":"J Coll Physicians Surg Pak"},{"issue":"7","key":"7611_CR114","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/art.42465","volume":"75","author":"JT Sanes","year":"2023","unstructured":"Sanes JT, Costello CE, Steere AC. Heightened proinflammatory glycosylation of borrelia burgdorferi IgG antibodies in synovial fluid in patients with antibiotic-refractory lyme arthritis. Arthritis Rheumatol. 2023;75(7):1263\u201374.","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"7611_CR115","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1038\/s41590-024-01916-8","volume":"25","author":"J Gaifem","year":"2024","unstructured":"Gaifem J, Rodrigues CS, Petralia F, Alves I, Leite-Gomes E, Cavadas B, et al. A unique serum IgG glycosylation signature predicts development of Crohn\u2019s disease and is associated with pathogenic antibodies to mannose glycan. Nat Immunol. 2024;25(9):1692\u2013703.","journal-title":"Nat Immunol"},{"issue":"3","key":"7611_CR116","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/art.43018","volume":"77","author":"H Achten","year":"2024","unstructured":"Achten H, Meuris L, Deroo L, Jarlborg M, Decruy T, Deprez J, et al. Impact of IgG Fc glycosylation on disease dynamics in patients with primary sj\u00f6gren disease. Arthritis Rheumatol. 2024;77(3):311\u201321.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"7611_CR117","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.immuni.2024.10.002","volume":"58","author":"S Chakraborty","year":"2025","unstructured":"Chakraborty S, Cheng B-L, Edwards DL, Gonzalez JC, Chiu D-C, Zheng H, et al. Sialylated IgG induces the transcription factor REST in alveolar macrophages to protect against lung inflammation and severe influenza disease. Immunity. 2025;58(1):182\u201396.e10.","journal-title":"Immunity"},{"key":"7611_CR118","doi-asserted-by":"crossref","unstructured":"Burel JG, Wang W, Wuhrer M, Dedicoat M, Fletcher TE, Cunningham AF, et al. IgG glycosylation associates with risk of progression from latent to active tuberculosis. J Infect. 2024;88(3).","DOI":"10.1016\/j.jinf.2024.01.014"},{"key":"7611_CR119","doi-asserted-by":"crossref","unstructured":"Hoshi RA, Plav\u0161a B, Liu Y, Trbojevi\u0107-Akma\u010di\u0107 I, Glynn RJ, Ridker PM, et al. N-Glycosylation profiles of immunoglobulin G and Future cardiovascular events. Circ Res. 2024;134(5).","DOI":"10.1161\/CIRCRESAHA.123.323623"},{"key":"7611_CR120","doi-asserted-by":"crossref","unstructured":"Streng BMM, Van Coillie J, Wildenbeest JG, Binnendijk RS, Smits G, den Hartog G, et al. IgG1 glycosylation highlights premature aging in down syndrome. Aging Cell. 2024;23(7).","DOI":"10.1111\/acel.14167"},{"key":"7611_CR121","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2147\/JIR.S341906","volume":"15","author":"K So\u0142kiewicz","year":"2022","unstructured":"So\u0142kiewicz K, Krotkiewski H, J\u0119dryka M, Czeka\u0144ski A, Kratz EM. The alterations of serum IgG fucosylation as a potential additional new diagnostic marker in advanced endometriosis. J Inflammation Res. 2022;15:251\u201366.","journal-title":"J Inflammation Res"},{"issue":"11","key":"7611_CR122","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1021\/acscentsci.4c01157","volume":"10","author":"W Wang","year":"2024","unstructured":"Wang W, Maliepaard JCL, Damelang T, Vidarsson G, Heck AJR, Reiding KR. Human IgG subclasses differ in the structural elements of their N-Glycosylation. ACS Cent Sci. 2024;10(11):2048\u201358.","journal-title":"ACS Cent Sci"},{"issue":"5","key":"7611_CR123","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/glycob\/cwm017","volume":"17","author":"AJ Jones","year":"2007","unstructured":"Jones AJ, Papac DI, Chin EH, Keck R, Baughman SA, Lin YS, et al. Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. Glycobiology. 2007;17(5):529\u201340.","journal-title":"Glycobiology"},{"issue":"22","key":"7611_CR124","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","volume":"115","author":"E M\u00f6ssner","year":"2010","unstructured":"M\u00f6ssner E, Br\u00fcnker P, Moser S, P\u00fcntener U, Schmidt C, Herter S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type ii anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115(22):4393\u2013402.","journal-title":"Blood"},{"issue":"1","key":"7611_CR125","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1080\/19420862.2015.1112477","volume":"8","author":"F Courtois","year":"2016","unstructured":"Courtois F, Agrawal NJ, Lauer TM, Trout BL. Rational design of therapeutic mAbs against aggregation through protein engineering and incorporation of glycosylation motifs applied to bevacizumab. MAbs. 2016;8(1):99\u2013112.","journal-title":"MAbs"},{"issue":"2","key":"7611_CR126","doi-asserted-by":"publisher","first-page":"e207937","DOI":"10.1212\/WNL.0000000000207937","volume":"102","author":"C Antozzi","year":"2024","unstructured":"Antozzi C, Guptill J, Bril V, Gamez J, Meuth SG, Nowak RJ, et al. Safety and efficacy of nipocalimab in patients with generalized myasthenia gravis: results from the randomized phase 2 vivacity-MG study. Neurology. 2024;102(2):e207937.","journal-title":"Neurology"},{"key":"7611_CR127","doi-asserted-by":"publisher","first-page":"20029","DOI":"10.1038\/srep20029","volume":"7","author":"C Yu","year":"2016","unstructured":"Yu C, Gao K, Zhu L, Wang W, Wang L, Zhang F, et al. At least two Fc Neu5Gc residues of monoclonal antibodies are required for binding to anti-Neu5Gc antibody. Sci Rep. 2016;7:20029.","journal-title":"Sci Rep"},{"issue":"5","key":"7611_CR128","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.4049\/jimmunol.1800896","volume":"202","author":"M Bas","year":"2019","unstructured":"Bas M, Terrier A, Jacque E, Dehenne A, Pochet-B\u00e9ghin V, Beghin C, et al. Fc sialylation prolongs serum half-life of therapeutic antibodies. J Immunol. 2019;202(5):1582\u201394.","journal-title":"J Immunol"},{"key":"7611_CR129","doi-asserted-by":"publisher","first-page":"e00927","DOI":"10.1016\/j.btre.2025.e00927","volume":"48","author":"CJI Bulaon","year":"2025","unstructured":"Bulaon CJI, Jaratsittisin J, Rattanapisit K, Suwanchaikasem P, Guo S, Boonha K, et al. Glycoengineering of plant-produced pembrolizumab enhances FcRn binding and extends serum half-life in mice. Biotechnol Rep (Amst). 2025;48:e00927.","journal-title":"Biotechnol Rep (Amst)"},{"key":"7611_CR130","doi-asserted-by":"publisher","first-page":"175628642312132","DOI":"10.1177\/17562864231213240","volume":"16","author":"H Wiendl","year":"2023","unstructured":"Wiendl H, Abicht A, Chan A, Della Marina A, Hagenacker T, Hekmat K, et al. Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord. 2023;16:17562864231213240.","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"7611_CR131","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.kint.2019.12.025","volume":"97","author":"E Crickx","year":"2020","unstructured":"Crickx E, Weill JC, Reynaud CA, Mah\u00e9vas M. Anti-CD20-mediated B-cell depletion in autoimmune diseases: successes, failures and future perspectives. Kidney Int. 2020;97(5):885\u201393.","journal-title":"Kidney Int"},{"key":"7611_CR132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2019.06.001","volume":"64","author":"M Yasunaga","year":"2020","unstructured":"Yasunaga M. Antibody therapeutics and immunoregulation in cancer and autoimmune disease. Semin Cancer Biol. 2020;64:1\u201312.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"7611_CR133","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2022","unstructured":"Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022;81(1):100\u201307.","journal-title":"Ann Rheum Dis"},{"key":"7611_CR134","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ijbiomac.2020.04.147","volume":"158","author":"M Reslan","year":"2020","unstructured":"Reslan M, Sifniotis V, Cruz E, Sumer-Bayraktar Z, Cordwell SP, Kayser V. Enhancing the stability of adalimumab by engineering additional glycosylation motifs. Int J Biol Macromol. 2020;158:189\u201396.","journal-title":"Int J Biol Macromol"},{"issue":"16","key":"7611_CR135","doi-asserted-by":"publisher","first-page":"5992","DOI":"10.1073\/pnas.1402458111","volume":"111","author":"A Hiatt","year":"2014","unstructured":"Hiatt A, Bohorova N, Bohorov O, Goodman C, Kim D, Pauly MH, et al. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc Natl Acad Sci U S A. 2014;111(16):5992\u201397.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"7611_CR136","doi-asserted-by":"publisher","first-page":"6152","DOI":"10.1038\/s41467-025-61440-7","volume":"16","author":"B Sotomayor","year":"2025","unstructured":"Sotomayor B, Donahue TC, Mahajan SP, Taw MN, Hulbert SW, Bidstrup EJ, et al. Discovery of a single-subunit oligosaccharyltransferase that enables glycosylation of full-length IgG antibodies in bacteria. Nat Commun. 2025;16(1):6152.","journal-title":"Nat Commun"},{"issue":"10","key":"7611_CR137","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1002\/eji.200737581","volume":"37","author":"KS Nandakumar","year":"2007","unstructured":"Nandakumar KS, Collin M, Ols\u00e9n A, Nimmerjahn F, Blom AM, Ravetch JV, et al. Endoglycosidase treatment abrogates IgG arthritogenicity: importance of IgG glycosylation in arthritis. Eur J Immunol. 2007;37(10):2973\u201382.","journal-title":"Eur J Immunol"},{"issue":"39","key":"7611_CR138","doi-asserted-by":"publisher","first-page":"15005","DOI":"10.1073\/pnas.0808248105","volume":"105","author":"H Albert","year":"2008","unstructured":"Albert H, Collin M, Dudziak D, Ravetch JV, Nimmerjahn F. In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner. Proc Natl Acad Sci U S A. 2008;105(39):15005\u201309.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"7611_CR139","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1073\/pnas.0711271105","volume":"105","author":"M Collin","year":"2008","unstructured":"Collin M, Shannon O, Bj\u00f6rck L. IgG glycan hydrolysis by a bacterial enzyme as a therapy against autoimmune conditions. Proc Natl Acad Sci U S A. 2008;105(11):4265\u201370.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"7611_CR140","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.11.041","volume":"172","author":"JD Pagan","year":"2018","unstructured":"Pagan JD, Kitaoka M, Anthony RM. Engineered sialylation of pathogenic antibodies in vivo attenuates autoimmune disease. Cell. 2018;172(3):564\u201377.e13.","journal-title":"Cell"},{"key":"7611_CR141","doi-asserted-by":"crossref","unstructured":"Sneed SL, Reese BB, Laureano AF, Ratnapriya S, Fraschilla I, Jeffrey KL, et al. An engineered immunomodulatory IgG1 Fc suppresses autoimmune inflammation through pathways shared with i.v. immunoglobulin. J Clin Invest. 2024;134(4).","DOI":"10.1172\/JCI172980"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07611-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07611-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07611-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T12:02:59Z","timestamp":1770984179000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-025-07611-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,25]]},"references-count":141,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7611"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07611-y","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,25]]},"assertion":[{"value":"18 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"222"}}